Results 41 to 50 of about 17,718 (201)
Senses and Sciences, 2014 Objective: The study compares the effectiveness of an intravitreal slow-release dexamethasone implant respect to an intravitreal injection of a anti-VEGF, ranibizumab, in the treatment of diabetic macular edema (DME).
Elena Pacella +8 more
doaj +1 more source
Acta Ophthalmologica, EarlyView.Abstract Purpose To evaluate visual, anatomical and safety outcomes of aflibercept 8 mg in previously treated patients with neovascular age‐related macular degeneration (nAMD). Methods This retrospective study included nAMD patients switched to aflibercept 8 mg from prior anti‐VEGF therapies at Sahlgrenska University Hospital between February 2024 and ...
Imadeddin Abu Ishkheidem +5 more
wiley +1 more source
Neovascular age‐related macular degeneration without drusen
Acta Ophthalmologica, EarlyView.Abstract Purpose To describe the clinical characteristics and 1‐year follow‐up of patients with neovascular AMD (nAMD) without drusen in either eye. Methods This is a multicentre retrospective cohort study in three tertiary referral centres in The Netherlands. We included patients of 55 years or older with nAMD in one or both eyes, without the presence
Marc J. Sirks +9 more
wiley +1 more source
Journal of International Medical Research, 2020 Objective To compare the efficacy of ranibizumab plus fufang xueshuantong capsule (cFXST) with the efficacy of ranibizumab alone in treatment of exudative age-related macular degeneration.
Hai-Tao Pan +7 more
doaj +1 more source
Acta Ophthalmologica, EarlyView.Abstract Purpose To evaluate long‐term outcomes of anti‐VEGF therapy for nAMD using the Polish Retinal Therapeutic Program Monitoring Registry. Methods The cohort consisted of 63 840 eyes with nAMD qualified for treatment from 2016 to 2022, with follow‐up through 31 October 2023. Long‐term follow‐up (>5 years) was conducted for 7631 eyes.
Sławomir Teper +9 more
wiley +1 more source
Clinical &Experimental Ophthalmology, EarlyView.ABSTRACT Background To evaluate the 10‐year cumulative incidence, progression rates, and risk factors for macular atrophy (MA) in neovascular age‐related macular degeneration (nAMD) patients receiving long‐term anti‐vascular endothelial growth factor (VEGF) therapy.
Francesco Romano +13 more
wiley +1 more source
Industry‐Reported Financial Relationships Among American Ophthalmology Society Board Members
Clinical &Experimental Ophthalmology, EarlyView.ABSTRACT Background To assess financial disclosures of American ophthalmology society board members by comparing self‐reported disclosures with industry‐reported payments and examining characteristics linked to larger financial relationships. Methods In this retrospective, cross‐sectional study, we assessed all governance board members from American ...
Mostafa Bondok +4 more
wiley +1 more source
Outcomes and costs of Ranibizumab and Aflibercept treatment in a health-service research context
BMC Ophthalmology, 2018 Background To compare anti-VEGF treatments for macular disease in terms of costs and clinical outcomes. Methods We identified patients suffering from macular disease and treated either with aflibercept, ranibizumab or both at the largest public eye ...
Martin K. Schmid +9 more
doaj +1 more source
Implantable Drug Delivery Systems for Skeletal Muscles and Eyes
Advanced NanoBiomed Research, Volume 6, Issue 2, February 2026.This review highlights the different types of recent implantable drug delivery systems (IDDS) fabricated for a use with skeletal muscles, and with eyes. It presents the developments already made and the current research directions, showing the evolution of IDDS and their great diversity.
Serge Ostrovidov +8 more
wiley +1 more source
Clinical Interventions in Aging, 2013 Angie HC Fong,1 Timothy YY Lai1,2 1Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Hong Kong Eye Hospital, Kowloon, Hong Kong; 22010 Retina and Macula Centre, Tsimshatsui, Kowloon, Hong Kong Abstract: Neovascular ...
Fong AH, Lai TY
doaj